| Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank H Julkunen, A Cichońska, M Tiainen, H Koskela, K Nybo, V Mäkelä, ... Nature communications 14 (1), 604, 2023 | 205 | 2023 |
| Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population H Julkunen, A Cichońska, PE Slagboom, P Würtz, ... elife 10, e63033, 2021 | 152 | 2021 |
| Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects H Julkunen, A Cichonska, P Gautam, S Szedmak, J Douat, T Pahikkala, ... Nature communications 11 (1), 6136, 2020 | 100 | 2020 |
| Learning with multiple pairwise kernels for drug bioactivity prediction A Cichonska, T Pahikkala, S Szedmak, H Julkunen, A Airola, M Heinonen, ... Bioinformatics 34 (13), i509-i518, 2018 | 84 | 2018 |
| Integrative analysis of metabolite GWAS illuminates the molecular basis of pleiotropy and genetic correlation CJ Smith, N Sinnott-Armstrong, A Cichońska, H Julkunen, EB Fauman, ... Elife 11, e79348, 2022 | 38 | 2022 |
| Effects of general and central adiposity on circulating lipoprotein, lipid, and metabolite levels in UK Biobank: a multivariable Mendelian randomization study JA Bell, TG Richardson, Q Wang, E Sanderson, T Palmer, V Walker, ... The Lancet Regional Health–Europe 21, 2022 | 30 | 2022 |
| Nightingale Health UK Biobank Initiative Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population H Julkunen, A Cichońska, PE Slagboom, P Würtz Elife 10, e63033, 2021 | 26 | 2021 |
| Blood biomarker score identifies individuals at high risk for severe COVID-19 a decade prior to diagnosis: metabolic profiling of 105,000 adults in the UK Biobank Nightingale Health UK Biobank Initiative, H Julkunen, A Cichońska, ... MedRxiv, 2020.07. 02.20143685, 2020 | 11 | 2020 |
| Atlas of plasma nuclear magnetic resonance biomarkers for health and disease in 118,461 individuals from the UK Biobank H Julkunen, A Cichońska, M Tiainen, H Koskela, K Nybo, V Mäkelä, ... medRxiv, 2022.06. 13.22276332, 2022 | 10 | 2022 |
| Metabolomic and genomic prediction of common diseases in 477,706 participants in three national biobanks Nightingale Health Biobank Collaborative Group, JC Barrett, T Esko, ... medRxiv, 2023.06. 09.23291213, 2023 | 9 | 2023 |
| A solution for large scale nonlinear regression with high rank and degree at constant memory complexity via latent tensor reconstruction S Szedmak, A Cichonska, H Julkunen, T Pahikkala, J Rousu arXiv preprint arXiv:2005.01538, 2020 | 8 | 2020 |
| Dominant role of abdominal adiposity in circulating lipoprotein, lipid, and metabolite levels in UK Biobank: Mendelian randomization study JA Bell, TG Richardson, Q Wang, E Sanderson, T Palmer, V Walker, ... medRxiv, 2021.05. 29.21258044, 2021 | 7 | 2021 |
| Nightingale Health, UKBI Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. Elife 10, doi: 10.7554 H Julkunen, A Cichonska, PE Slagboom, P Wurtz Elife 63033, 2021 | 5 | 2021 |
| Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. Elife H Julkunen, A Cichońska, PE Slagboom, P Würtz, ... eLife Sciences Publications Ltd, 2021 | 4 | 2021 |
| comboFM: leveraging multi-way interactions for systematic prediction of drug combination effects H Julkunen, A Cichonska, P Gautam, S Szedmak, J Douat, T Pahikkala, ... BioRxiv, 2020.09. 02.278986, 2020 | 4 | 2020 |
| Predictive modeling of anticancer efficacy of drug combinations using factorization machines H Julkunen | 3 | 2019 |
| Machine learning for precision medicine H Julkunen Aalto University, 2025 | | 2025 |
| Metabolomic and genomic prediction of common diseases in 700,217 participants in three national biobanks Nature Communications 15 (1), 10092, 2024 | | 2024 |
| Use of glycoprotein acetyls for determining the risk of developing atrial fibrillation and/or flutter H Julkunen, P Würtz US Patent App. 18/277,838, 2024 | | 2024 |
| Method for determining whether a subject is at risk of dying from breast cancer or prostate cancer H Julkunen, P Würtz US Patent App. 18/275,351, 2024 | | 2024 |
